Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication

Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirokawa, Esuteru, Watanabe, Satomi, Sakai, Kazuko, Takeda, Masayuki, Sato, Chihiro, Takahama, Takayuki, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365001/
https://www.ncbi.nlm.nih.gov/pubmed/34240806
http://dx.doi.org/10.1111/1759-7714.14081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365001/
https://www.ncbi.nlm.nih.gov/pubmed/34240806
http://dx.doi.org/10.1111/1759-7714.14081

Ejemplares similares